Canntab Announces its Entrance into the Nova Scotia Cannabis Market

Published: August 23, 2022

Canntab Announces its Entrance into the Nova Scotia Cannabis Market

Canntab Therapeutics Limited, the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to provide an update on its recent product delivery of our unique pharmaceutical cannabinoid solutions to the Nova Scotia Liquor Corporation (NSLC). On August 15th, 2022, Canntab completed its first shipment of 5mg and 10mg THC InstaCann tablets to the NSLC, totaling 300 bottles of each SKU. These products are now available on the NSLC’s online platform and will be available in their brick-and-mortar stores starting today, August 22nd, 2022.

“This is a continuation of our efforts to expand our sphere of influence across not only Ontario, but the rest of the Canadian provinces,” says Richard Goldstein, co-founder, CFO, and interim CEO. Mr. Goldstein continues, “while we have our online ecommerce store open for our medical patients, getting into more retail locations while also being listed with the NSLC’s online platform is another positive move for Canntab. We are leaders in the oral delivery system of cannabis in the market today.”

About Canntab Therapeutics Limited
Canntab is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of cannabinoid tablet formulations in multiple doses and timed-release combinations. Long referred to as Cannabis 3.0 by the Company, Canntab’s proprietary cannabinoid tablet formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world. These include once a day and extended-release formulations, both providing an accurate dose and improved shelf stability. Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes License and a Cannabis Research License.